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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comincreased in the bifurcation group. However the overall rate of deﬁnite or probable ST
was similar (1.4% vs. 0.7%, p¼0.08). Of the 7 cases of ST in the bifurcation sub-
group, 6 occurred in patients treated with a 2 stent strategy.
Conclusions: These preliminary results suggest that BES’s perform well in bifurca-
tion lesions and that ST seems to be inﬂuenced by the stenting strategy.
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Background: The coronary bifurcation lesions are still problematic issue in inter-
ventional cardiology and their occurrence is a marker of increased procedural and
long-term risk. The aim of present study was to compare clinical effectiveness and
safety of newest version of BiOSS stent – BiOSS Lim, in comparison with historical
version, covered with paclitaxel, BiOSS Expert.
Methods: From September 2009, all patients with coronary bifurcation lesions
deemed appropriate for implantation of dedicated bifurcation stent BiOSS (Bifurcation
Optimization Stent System, Balton, Poland) were included in prospective registry. The
patients were excluded if they had ST-segment elevation myocardial infarction
(STEMI), life expectancy less than one year, inability to take double antiplatelet
therapy for 12 months, with bifurcation lesions Medina 001 and patient requiring more
than one BiOSS stent implantation. All patients had clinical examination at 30 days
and every 3 months thereafter were contacted by phone call.
Results: A 106 patients were included - 80 patients with BiOSS Lim (sirolymus-
eluting) and 26 with BiOSS Expert (paclitaxel-eluting). The mean age was 6410,
71% males, 39% diabetics, 35% had previous MI, 43% had previous PCI, 13%
previous CABG. Most of the patients were in CCS class 3-4 or were unstable (68%).
Multivessel disease or left main distal bifurcation occurred in 76%. True bifurcation
lesions occurred in 51% (Medina xx1). There were 2 postprocedural myocardial in-
farctions (1.9%) (CK-MB elevation). Increase of tropoinin I >3xnormal was observed
in 18%. At mean follow-up of 12 months there were 2 deaths (2%) and 3 spontaneous
myocardial infarctions (2.8%). A 12 angiographic restenotic lesions were detected
(11.3%), of which 10 (9.4%) were treated by repeat angioplasty. In total, the rate of
major adverse cardiac events (death, myocardial infarction and repeat PCI) was 10.4%
(11 pts). The rate of TLR (5%) and MACEs (7.5%) with BiOSS Lim was signiﬁcantly
lower than in BiOSS Expert (p< .005)
Conclusions: The new sirolymus eluting dedicated coronary bifurcation stent BiOSS
Lim demonstrated marked superiority over its paclitaxel version, with excellent
clinical efﬁcacy and safety in mid-term follow-up.Coronary Lesions - CTO
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Background: Chronic total occlusion (CTO) represents one of the most challenging
lesion subset in interventional cardiology. The Italian Registry of Chronic Total Oc-
clusion (IRCTO) aims to provide current data on CTO prevalence, and on clinical and
angiographic characteristics and management of CTO patients. Moreover, it reports
the effect of CTO treatment strategy on long-term prognosis.
Methods: The IRCTO is a prospective real world multicentre registry, which enrolled
patients showing at least 1 CTO at coronary angiography in thirteen high volume
catheterization labs across Italy. Clinical and angiographic data of all CTO patients,
regardless of chosen treatment strategy (medical therapy [MT], percutaneous coronaryB56 JACC Vol 64/11/Suppl Bintervention [PCI], or coronary artery bypass grafting [CABG]), were collected into a
web database.In order to compare outcomes of patients undergoing different treatment
strategies, while minimizing the impact of treatment selection bias and potential
confounding, a rigorous adjustment by propensity score matching (PSM) was
performed.
Results: A total of 1,777 patients were enrolled, among these 826 (46,5%) patients
were managed by MT, 776 (43,7%) by PCI and the last 175 (9.8%) were referred to
CABG. At one year, patients undergoing successful PCI showed lower rate of
MACCE and cardiovascular death in comparison with patients treated with MT and
CABG (2.6% vs 8.2% and vs 6.9%, p< 0.001 and p< 0.01, and 1.4% vs 4.7% and vs
6.3%, p< 0.001 and p< 0.001 respectively). After PSM analysis patients treated with
PCI showed lower incidence of death, acute myocardial infarction and re-hospitali-
zation rate in comparison with MT (4.4% vs 1.5% p< 0.001, 2.9% vs 1.1% p¼0.03
and 4.4% vs 2.3% p¼0.04 respectively).
Conclusions: The present study provides current data on prevalence, characteristics
and management of CTO patients. More importantly, our data showed as percuta-
neous revascularization of a CTO leads to a signiﬁcantly improved survival rate and a
reduction in MACCE at 1-year follow-up in comparison with MT and/or CABG
management.
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Background: Clinical beneﬁt of successful chronic total occlusion (CTO) revascu-
larization by percutaneous coronary intervention (PCI) remains under discussion. This
study aimed to assess health-related quality of life (HRQL), functional status and
myocardial ischemia after successful CTO PCI.
Methods: Between 2012 and 2014, 106 eligible patients who were scheduled for PCI
of a true CTO were included in this prospective study. HRQL questionnaire, six-
minute walk test and CMR studies were plan to be performed before and at 6-month
follow-up of patients with successful PCI of CTO. HRQL, was assessed by the short
form 36-item (SF-36) health survey, which measure health across eight-dimension,
including physical and mental components. Functional status was assessed by the six-
minute walk test. Regarding CMR study, the severity of ischemia was assessed by
means of an ischemic score index (ISI) based on the 16-segment model of analysis of
the left ventricle and calculated from the following items (relative weight is given in
brackets): 1) extension of the defect (20%); 2) persistence along the duration of the
perfusion sequence (20%); 3) transmurality (20%); and 4) inducibility of contractile
regional dysfunction under adenosine (40%).
Results: CTO recanalization signiﬁcantly improved all the components of the HRQL
test during follow-up (n¼66): patients with successful procedure experienced less
physical activity limitation (p< 0.001), rarer general pain episodes (p< 0.001) and
greater mental aspects (p< 0.001). The distance walked in the six-minute test (n¼59)
improved at follow-up (405.4  115.3 pre-PCI vs. 451.4  106.2 meters post-PCI, p<
0.001. Post-PCI, chest pain episodes decreased after the six-minute test, p< 0.001. A
correlation was found between distance walked in the six-minute test and physical
components of HRQL, r¼0.58, p< 0.001. Finally, total ISI by CRM (n¼37) also
improved signiﬁcantly, after PCI (basal 20.5 9.9% vs. post-PCI 4  9.2, p< 0.001).
Conclusions: CTO recanalization leads to a reduction in inducible myocardial
ischemia assessed by CMR. Furthermore, patients signiﬁcantly improved health-
related quality of life and experienced less physical activity limitation, and chest pain
episodes.
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Background: Chronic total occlusion (CTO) percutaneous coronary intervention
(PCI) can provide signiﬁcant clinical beneﬁts, yet there is limited information on its
success and safety in unselected patient populations. We sought to describe
contemporary frequency, predictors, and outcomes of CTO PCI in the United States.
Methods: We analyzed the frequency and outcomes of CTO PCI compared to non-
CTO PCI in elective patients, and of successful vs. failed CTO PCI, between July 1
2009 and March 31 2013 in the NCDR CathPCI Registry. Generalized estimatingj September 13–17, 2014 j TCT Abstracts/Coronary Lesions - CTO
